The US Food and Drug Administration (FDA) has proposed a new ingredient, Bemotrizinol, for sunscreens, which could offer superior protection against UV A and B rays compared to current US-approved products. This chemical, already used in Europe, Australia, and Asia, has been criticized by FDA Commissioner Marty Makary for the US's slow approval process, which he believes has left Americans with fewer options. The proposed concentration of Bemotrizinol in sunscreens is up to 6%.
Sunscreen is crucial for preventing skin cancer and premature aging, but health officials note that most people don't use enough. It's recommended to use sunscreen, wear sunglasses, and protective clothing to shield the skin from UV damage. Skin cancer is the most common cancer in America, with 6.1 million adults treated annually for basal cell and squamous cell carcinomas, according to the Centers for Disease Control and Prevention.
The proposed inclusion of Bemotrizinol in sunscreens is a positive step, as it could provide better protection and potentially reduce the risk of skin cancer. However, the slow approval process in the US has been a concern, and experts like Dr. Makary are urging for faster adoption of new sunscreen technologies to ensure Americans have access to the best and most effective products.
